Aurinia Pharmaceuticals Inc (STU:IKAP)
€ 9.252 -0.386 (-4%) Market Cap: 1.32 Bil Enterprise Value: 1.07 Bil PE Ratio: 0 PB Ratio: 3.73 GF Score: 84/100

Q4 2019 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Mar 05, 2020 / 09:30PM GMT
Release Date Price: €16.7 (+2.45%)
Operator

Good afternoon, and welcome to the Aurinia Pharmaceuticals Fourth Quarter and Year-End 2019 Results Conference Call. (Operator Instructions) Please note, this conference is being recorded.

I will now turn the conference over to your host, Dr. Glenn Schulman, Head of Investor Relations. Thank you. You may begin.

Glenn Schulman
Aurinia Pharmaceuticals Inc. - SVP of Corporate Communications & IR

Thanks, Diego, and good afternoon, everyone. Welcome to Aurinia's Year-End 2019 Results Conference Call.

Joining me on the call today from the Aurinia team are Mr. Peter Greenleaf, President and CEO; our CFO, Dennis Bourgeault; Dr. Neil Solomons, our Chief Medical Officer; Mr. Michael Martin, Chief Operating Officer; and Mr. Max Colao, our recently appointed Chief Commercial Officer. Following some prepared remarks, the team will also be available for questions during the Q&A session.

So this afternoon, we issued our press release detailing fourth quarter and year-end 2019 financial results. The press release and associated financial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot